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Background. Recent data suggest that the renin-angiotensin system may be involved in triglyceride (TG) metabolism. We explored
the eﬀect of the common A1166C and C573T polymorphisms of the angiotensin II type 1 receptor (AT1R) gene on postprandial
lipemia.Methods. Eighty-two subjects measured daytime capillary TG, and postprandial lipemia was estimated as incremental area
under the TG curve. The C573T and A1166C polymorphisms of the AT1R gene were determined. Results. Postprandial lipemia
was significantly higher in homozygous carriers of the 1166-C allele (9.39 ± 8.36mM∗h/L) compared to homozygous carriers of
the 1166-A allele (2.02 ± 6.20mM∗h/L) (P < 0.05). Postprandial lipemia was similar for the diﬀerent C573T polymorphisms.
Conclusion. The 1166-C allele of the AT1R gene seems to be associated with increased postprandial lipemia. These data confirm
the earlier described relationships between the renin-angiotensin axis and triglyceride metabolism.
1. Introduction
Hypertriglyceridemia is an independent risk factor for the
development of cardiovascular disease (CAD) [1, 2]. Recent
prospective studies have shown that nonfasting TG levels
are also associated with an increased risk in cardiovascular
disease [3] and are possibly an even stronger predictor for
CAD than fasting TG considering that humans are mostly
in the nonfasting state [4, 5]. There is increasing interest
to identify genes involved in the regulation of postprandial
lipemia. The classical genes influencing TG metabolism like
lipoprotein lipase or the APOE receptor are well known, but
several others have been identified recently [6–8]. The large
individual variability of TG levels cannot be fully explained
by eﬀects of these genes only. Most likely, environmental
and dietary eﬀects are the most important determinants of
TG levels. However, unexpected eﬀects by non-lipid-related
genes have also been described. The renin angiotensin system
mutational polymorphisms has been related to the metabolic
syndrome and consequently to hypertriglyceridemia [9]. In
the last decade, the beneficial eﬀect of blockade of the
renin-angiotensin system have been demonstrated in a wide
variety of cardiovascular diseases, from heart failure to stable
coronary artery disease and diabetic as well as nondiabetic
chronic nephropathies [10, 11]. Therefore, the aim of the
present study was to explore possible relationships between
the angiotensin II type 1 receptor (AT1R) polymorphisms,
A1166C and C573T, and fasting and postprandial triglyc-
eridemia.
2. Material and Methods
2.1. Subjects. This paper is part of an ongoing study
aimed at evaluating inheritable risk factors for premature
atherosclerosis, metabolic disturbances, and genetic deter-
minants. Normocholesterolemic CAD patients and their
first-degree relatives were asked to participate. All CAD
index patients had coronary sclerosis established by coronary
angiography at a young age (before the age of 50 in men
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and of 60 in women) and had undergone a percutaneous
transluminal coronary angioplasty (PTCA) at the Heart
Lung Centre Utrecht. Exclusion criteria for index patients
were the presence of diabetes mellitus, body mass index
(BMI) >30 kg/m2, renal and/or liver failure, fasting plasma
cholesterol >6.5mmol/L (without lipid lowering medica-
tion), the presence of the apo E2/E2 genotype, the use of
alcohol of more than 3 units a day, and a cardiac event or
revascularization procedure during six months before the
start of the study. Lipid-loweringmedication, which was used
by five patients, was stopped for 5 weeks before entering the
study.
Only families of which at least two first-degree relatives
were available for analysis were included. Exclusion criteria
for family members were similar to those for the CAD
index patients, except they should not have a medical
history of CAD. Information about subjects’ personal and
family histories of cardiovascular disease was obtained by
a standardised questionnaire. All participants were invited
for a screening visit at the hospital. On the morning of
inclusion blood pressure, weight, length, and waist and hip
circumference weremeasured and a fasting blood sample was
obtained for baseline determinations. The study protocol was
approved by the Human Investigation Review Committees of
the University Medical Centre Utrecht, and written informed
consent was obtained from all participants.
2.2. TG Self-Measurements. Self-measurement of capillary
TG was performed with a TG-specific point-of-care testing
device (Accutrend GCT, Roche Diagnostics, Germany) [12–
14]. Subjects were instructed to wash and dry their hands
thoroughly before each measurement. With a lancing device,
a drop of blood (30 µL) from the finger was obtained
which was applied to the TG test strip in the TG analyser.
Subsequently, TG concentrations were measured by a process
of dry chemistry and colorimetry. Participants measured
their capillary TG on three diﬀerent days at six standardized
time points: fasting, before and three hours after lunch
and dinner, and at bedtime. The results were recorded
in a diary. Subjects were requested to refrain from heavy
physical activity on the measurement days. Participants did
not receive recommendations concerning the frequency and
composition of the meals and were requested to use their
regular diet during the study. In case of one or more missing
measurements during a day, the data for that particular day
were not used for construction of an average diurnal TG
profile. The mean diurnal TG profile of 2 or 3 days was used
for statistical analysis.
The measurement range of the Accutrend GCT for
capillary TG is 0.80 to 6.86mmol/L. The Accutrend sys-
tem detects TG reliably, regardless of the nature of the
triglyceride-carrying lipoprotein species (chylomicrons or
VLDL particles) [15]. Variation coeﬃcients for diﬀerent cap-
illary TG concentrations are 3.3% for high TG (6.12mmol/L)
and 5.3% for low TG (1.81mmol/L) [15]. The correlation
coeﬃcient between Accutrend capillary TG measurements
and plasma measurements according to enzymatic methods
is 0.94 [15]. Furthermore, in healthy lean subjects diurnal
capillary TG profiles correlate to postprandial lipemia
assessed by standardised oral fat-loading tests [13]. In
addition, diurnal triglyceridemia estimated with 6 measure-
ments over the day was not diﬀerent compared to hourly
measurements, suggesting that the chosen time points are
representative for the daylong study period [14].
2.3. Analytical Methods. Blood was collected at inclusion
after a 12 hours fast for measurement of plasma lipids,
apolipoproteins, insulin, and glucose. Cholesterol, plasma
triglyceride, and HDL cholesterol (obtained after precipita-
tion with dextran sulphate/MgCl2) were determined using
a Vitros 250 analyser (Johnson & Johnson Rochester, NY,
USA). Plasma apo B was measured by nephelometry using
apo B monoclonal antibodies (Behring Diagnostics NV,
OSAN 14/15). Plasma apo AI wasmeasured by nephelometry
using apo AI monoclonal antibodies (Behring Diagnostics
NV, OUED 14/15). Plasma glucose was measured by glucose
oxidase dry chemistry (Vitros GLU slides) and colorimetry
and insulin was measured by competitive radio immunoas-
say with polyclonal antibodies. The HOMA-IR index (=
glucose (mmol/L) ∗insulin (mU/L)/22.5) was calculated for
estimation of insulin sensitivity.
2.4. Genotyping Procedures. Genotypes were determined as
described previously [16]. A blood sample for polymorphism
analysis was obtained from each patient in the morning after
a minimum of 8 h fasting. Genomic DNAwas extracted from
white blood cells using silica gel polymer [17]. Reactions
were conducted using DNA amplification in a final volume
of 15 µL containing 0.75 µmol/L of each primer, 75 µmol/L
of each NTP, 2 ng/µL DNA, 1.5mmol/L MgCl2, 75mmol/L
Tris-HCl (pH 9.0), 20mmol/L (NH4)2SO4, 5mmol/L KCl,
and 0.2U/µL Netzyme DNA polymerase (Need, SL, Valen-
cia, Spain). The DNA was amplified for 40 cycles with
denaturation at 94◦C for 90 s (PTC-100 thermal cycler, MI
Research). The polymerase chain reaction (PCR) products
underwent electrophoresis using 2% agarose gel. DNA was
visualized with ethidium bromide staining. The region of
the AT1R located between nucleotides 423 and 1278 of the
cDNA was amplified using oligonucleotides 5′-GGC TTT
GCT TTG TCT TGT TG and 5′-AAT GCT TGT AGC
CAA AGT CAC CT as sense and antisense primers, respec-
tively. Amplification was conducted as described above. The
A1166C and C573T polymorphisms of the AT1R gene were
analyzed simultaneously by PCR using the technique which
is described in detail elsewhere [18].
2.5. Statistical Analysis. Values are given as mean ± standard
deviation (SD). Comparisons between CAD index patients
and healthy relatives were performed with Student’s t-
test. Comparisons between the diﬀerent genotypes of the
polymorphisms were performed with one-way ANOVA with
Bonferroni correction for parametric data and Pearson’s Chi-
square for nonparametric data. In the case of TG, insulin, and
HOMA index, calculations were performed after logarithmic
transformation; however, untransformed concentrations are
shown in the text, tables, and figures. Calculations of
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TG-AUCs were performed with GraphPad Prism version
3.0 for Windows (GraphPad Software, San Diego, Calif,
USA) using nonlogarithmic transformed TG concentrations.
Postprandial lipemia was defined as the incremental area
under the capillary TG curve after correction for fasting
capillary TG (dTG-AUC). For statistical analysis, PASW
version 18.0 was used. Statistical significance was reached
when P < 0.05 (two sided).
3. Results
A total of 82 subjects were included. Sixteen of them were
normocholesterolemic CAD patients, and there were 66
healthy relatives. The frequency of the T-allele for the C573T
gene polymorphisms was 65%. The C-allele for the A1166C
gene polymorphisms showed a frequency of 60%. No
significant diﬀerences in allele distribution between patients
and family members were found. All polymorphisms were
in Hardy–Weinberg equilibrium. Baseline characteristics
for the A1166C and C573T polymorphisms are shown in
Tables 1 and 2, respectively. No significant diﬀerences were
found among the diﬀerent A1166C polymorphisms, but
the BMI was significantly diﬀerent among the C573T
polymorphisms (P = 0.047).
Postprandial lipemia expressed as the dTG-AUC was
significantly higher in homozygous carriers of the 1166-
C allele (9.39 ± 8.36mM∗h/L) compared to homozygous
carriers of the A-allele (2.02 ± 6.20 mM∗h/L) (P < 0.05).
Postprandial lipemia in carriers of the CA polymorphism of
the A1166C gene was 3.65± 7.42mM∗h/L, which was inter-
mediate to the CC and AA polymorphisms, without reaching
statistical significance (Figure 1). Postprandial lipemia was
similar for the diﬀerent C573T gene polymorphisms ranging
from 4.05 ± 9.54mM∗h/L for the CC polymorphism,
3.82 ± 4.75mM∗h/L for the CT polymorphism, to 2.17 ±
7.00mM∗h/L for the TT polymorphism (Figure 2).
4. Discussion
It has been suggested that 40% of the variation in triglyceride
concentrations in the population is caused by genetic
heritability [19]. This study shows for the first time increased
postprandial lipemia in homozygous carriers of the 1166-
C allele of the AT1R gene. It should be noted that the
number of subjects in this study was small and only seven
subjects were homozygous carriers of the 1166-C-allele.
Despite the fact that fasting TG, the strongest determinant
of postprandial lipemia, was similar for the groups, the
CC-group showed an exaggerated postprandial response.
Disturbances of lipid metabolism are frequent in patients
with hypertension, metabolic syndrome, and cardiovascu-
lar disease; together they share numerous susceptibility
genes [6]. Two experimental studies demonstrated increased
contraction of human arteries in homozygous carriers of
the 1166-C allele [20, 21]. In hypertensive patients with
metabolic syndrome, the presence of the CC1166 genotype
was a risk factor for central obesity and dyslipidemia [9].
Furthermore, the C-allele of the A1166C polymorphism
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Figure 1: Diurnal capillary triglyceride (cTG) patterns for A1166C
polymorphisms. Fasting cTG was similar for the three diﬀerent
polymorphisms, but homozygous carriers of the 1166-C allele
showed a significantly increased incremental area under the cap-
illary triglyceride curve compared to homozygous carriers of the
1166-A allele (P < 0.05).
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Figure 2: Diurnal capillary triglyceride patterns for C573T poly-
morphisms. No significant diﬀerences for the polymorphisms were
found in the incremental area under the capillary triglyceride curve
as a marker for postprandial lipemia.
has been associated with a decreased endothelial response
to statin treatment measured with brachial artery flow-
mediated dilation [22]. The C-allele also predisposes to an
increased risk for stroke, especially in combination with
hypertension [23]. It is known that endothelial function
becomes impaired by increased TG concentrations after
an oral fat-loading test [24, 25]. All these data suggest
that the A1166C polymorphism of the AT1R gene shares
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Table 1: Baseline characteristics for A1166C polymorphisms. Data are given as mean ± standard deviation unless stated otherwise.
AA (N = 34) CA (N = 41) CC (N = 7) P-value
Age (years) 43.8± 16.5 41.3± 11.0 50.0± 12.1 NS
Male gender 18 (53%) 22 (54%) 3 (43%) NS
CAD 9 (26%) 5 (12%) 2 (29%) NS
BMI 25.1± 3.4 25.6± 4.7 26.5± 2.9 NS
Waist (cm) 91.8± 11.3 92.0± 15.6 96.0± 11.8 NS
Systolic RR (mmHg) 126.6± 10.6 124.2± 14.5 127.9± 10.4 NS
Diastolic RR (mmHg) 82.8± 9.2 82.1± 8.1 84.3± 6.1 NS
Total cholesterol (mmol/L) 5.5± 0.9 5.3± 1.0 5.6± 0.6 NS
LDL-C (mmol/L) 3.7± 0.8 3.5± 0.9 3.6± 0.7 NS
HDL-C (mmol/L) 1.26± 0.33 1.18± 0.30 1.35± 0.40 NS
Plasma TG (mmol/L) 1.34± 0.62 1.37± 0.70 1.29± 0.79 NS
ApoB (g/L) 0.99± 0.23 0.93± 0.23 0.94± 0.20 NS
ApoA-I (g/L) 1.37± 0.19 1.33± 0.23 1.30± 0.28 NS
HOMA-IR 2.31± 1.41 2.51± 1.96 2.70± 1.75 NS
CAD: coronary artery disease, BMI: body mass index, RR: blood pressure, TG: triglyceride, Apo: apolipoprotein, HOMA-IR: homeostatic model assessment.
Table 2: Baseline characteristics for C573T polymorphisms. Data are given as mean ± standard deviation unless stated otherwise.
CC (N = 29) CT (N = 34) TT (N = 19) P-value
Age (years) 45.0± 10.4 40.7± 15.4 44.3± 15.0 NS
Male gender 13 (44.8%) 20 (58.8%) 10 (52.6%) NS
CAD 6 (20.7%) 4 (14.7%) 5 (26.3%) NS
BMI 26.6± 5.0 25.5± 3.6 23.7± 2.5 P = 0.047
Waist (cm) 95.2± 15.7 92.0± 12.8 88.2± 10.5 NS
Systolic RR (mmHg) 125.6± 10.9 125.3± 14.9 125.8± 11.2 NS
Diastolic RR (mmHg) 84.0± 7.5 80.6± 8.0 84.2± 9.8 NS
Total cholesterol (mmol/L) 5.6± 1.0 5.2± 0.8 5.4± 1.0 NS
LDL-C (mmol/L) 3.8± 1.0 3.4± 0.8 3.5± 0.9 NS
HDL-C (mmol/L) 1.29± 0.34 1.17± 0.29 1.24± 0.34 NS
Plasma TG (mmol/L) 1.27± 0.55 1.43± 0.73 1.33± 0.73 NS
ApoB (g/L) 0.97± 0.22 0.95± 0.22 0.94± 0.26 NS
ApoA-I (g/L) 1.35± 0.21 1.34± 0.23 1.35± 0.20 NS
HOMA-IR 2.77± 2.34 2.45± 1.40 2.45± 1.72 NS
CAD: coronary artery disease, BMI: body mass index, RR: blood pressure, TG: triglyceride, Apo: apolipoprotein, HOMA-IR: homeostatic model assessment.
susceptibility with common disorders seen in metabolic
syndrome like postprandial lipemia.
The C573T polymorphism did not show any diﬀerences
in postprandial lipemia. A possible explanation is that it does
not influence the amino acid sequence of the encoded protein
although this polymorphism is located in the coding region
of the gene [21]. In contrast, the A1166C polymorphism
is located in a nontranslated region of the AT1R gene
but it has been suggested to be in linkage disequilibrium
with another, yet-unknown, functional mutation thus ex-
plaining the multiple associations of this polymorphism
with several diseases. However, contradictory results have
also been found which could not confirm the association
of the A1166C polymorphism with metabolic syndrome,
hypertension, or cardiovascular disease [26, 27]. In one study
the A1166C polymorphism was not related to triglyceride
concentrations, but this study was performed in a Hong
Kong Chinese population and only two subjects with the
CC genotype could be identified [28]. A very recent study
comprising more than 100,000 individuals did not find an
association between the A1166C polymorphism and blood
lipids, including TG [8]. However, the authors did not study
specifically postprandial lipemia.
5. Conclusions
Although contribution of the diﬀerent genes seems small,
there is evidence that genetic variations have a cumulative
eﬀect on the cardiovascular risk [18, 29, 30] and that
genetic variations modulate the eﬀect of environmental
factors on cardiovascular risk [31]. With the availability of
easy and quick gene mapping, it might be possible in the
future to genetically classify patients according to their risk,
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before the disease phenotype is manifest. This might lead
to preventive treatment of patients in the high-risk classes,
thus diminishing disease burden and preventing unnecessary
treatment of low-risk patients. In conclusion, we report that
postprandial lipemia is increased in homozygous carriers of
the C-1166 polymorphism of the AT1R gene. No association
was found between postprandial lipemia and the C573T
polymorphism.
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